Design and Analysis of Vaccine Studies

and Examples.- Overview of Vaccine Effects and Study Designs.- Immunology and Early Phase Trials.- Binomial and Stochastic Transmission Models.- and Deterministic Models.- Evaluating Protective Effects of Vaccination.- Modes of Action and Time-Varying VE.- Further Evaluation of Protective Effects.- Vaccine Effects on Post-Infection Outcomes.- Household-Based Studies.- Analysis of Households in Communities.- Analysis of Independent Households.- Assessing Indirect, Total, and Overall Effects.- Randomization and Baseline Transmission.- Surrogates of Protection.

[1]  R. M. Atwater.  Prevention of Whooping-cough by Vaccination , 1951, British medical journal.

[2]  P. Smith.  Retrospective assessment of the effectiveness of BCG vaccination against tuberculosis using the case-control method. , 1982, Tubercle.

[3]  I. Longini,et al.  The critical vaccination fraction for heterogeneous epidemic models. , 2003, Mathematical biosciences.

[4]  R. Morrow,et al.  Field trials of health interventions in developing countries : a toolbox , 1996 .

[5]  H. Fuerst.  The Swine Flu Affair: Decision Making on a Slippery Disease , 1980 .

[6]  J. Whitehead.  Fitting Cox's Regression Model to Survival Data Using Glim , 1980 .

[7]  T. Shakespeare,et al.  Observational Studies , 2003 .

[8]  M. Halloran,et al.  Randomization and baseline transmission in vaccine field trials , 2006, Epidemiology and Infection.

[9]  C P Farrington,et al.  On vaccine efficacy and reproduction numbers. , 2003, Mathematical biosciences.

[10]  Douglas G. Altman,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials , 2001, The Lancet.

[11]  S Greenland,et al.  Interpretation and estimation of summary ratios under heterogeneity. , 1982, Statistics in medicine.

[12]  M. Halloran,et al.  A Bayesian Framework for Estimating Vaccine Efficacy per Infectious Contact. , 2009, The annals of applied statistics.

[13]  M E Halloran,et al.  Efficiency of Estimating Vaccine Efficacy for Susceptibility and Infectiousness: Randomization by Individual Versus Household , 1999, Biometrics.

[14]  David J. Spiegelhalter,et al.  Analysis of longitudinal binary data from multiphase sampling , 1998 .

[15]  R. L. Prentice,et al.  A case-cohort design for epidemiologic cohort studies and disease prevention trials , 1986 .

[16]  A. Melegaro,et al.  Pneumococcal carriage in United Kingdom families: estimating serotype-specific transmission parameters from longitudinal data. , 2007, American journal of epidemiology.

[17]  A. Takala,et al.  Nasopharyngeal carriage of Streptococcus pneumoniae in Finnish children younger than 2 years old. , 2001, The Journal of infectious diseases.

[18]  Jeffrey S. A. Stringer,et al.  Design of the HIV Prevention Trials Network (HPTN) Protocol 054: A cluster randomized crossover trial to evaluate combined access to Nevirapine in developing countries , 2003 .

[19]  Michael E. Sobel,et al.  What Do Randomized Studies of Housing Mobility Demonstrate? , 2006 .

[20]  C. Struchiner,et al.  Evaluation of SPf66 malaria vaccine efficacy in Brazil. , 1998, The American journal of tropical medicine and hygiene.

[21]  Samuel Karlin,et al.  A First Course on Stochastic Processes , 1968 .

[22]  S P Azen,et al.  OBTAINING CONFIDENCE INTERVALS FOR THE RISK RATIO IN COHORT STUDIES , 1978 .

[23]  M. Halloran,et al.  Exposure efficacy and change in contact rates in evaluating prophylactic HIV vaccines in the field. , 1994, Statistics in medicine.

[24]  M Elizabeth Halloran,et al.  Effects of pertussis vaccination on transmission: vaccine efficacy for infectiousness. , 2003, Vaccine.

[25]  M. Halloran,et al.  Causal Inference in Infectious Diseases , 1995, Epidemiology.

[26]  G. Calandra,et al.  Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989. , 1991, Pediatrics.

[27]  P. Ward,et al.  Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. , 2004, The Journal of infectious diseases.

[28]  H. Hallander,et al.  A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. , 1996, The New England journal of medicine.

[29]  On the distribution of vaccine protection under heterogeneous response. , 1993, Mathematical biosciences.

[30]  C. Farrington,et al.  Age-specific efficacy of pertussis vaccine during epidemic and non-epidemic periods , 1993, Epidemiology and Infection.

[31]  A. Phillips,et al.  CONFOUNDING IN EPIDEMIOLOGIC STUDIES , 1993 .

[32]  M. Gahr,et al.  Efficacy of acellular pertussis vaccine in early childhood after household exposure. , 1996, JAMA.

[33]  D. Sack,et al.  Field trial of oral cholera vaccines in Bangladesh: serum vibriocidal and antitoxic antibodies as markers of the risk of cholera. , 1991, The Journal of infectious diseases.

[34]  O. Diekmann,et al.  On the definition and the computation of the basic reproduction ratio R0 in models for infectious diseases in heterogeneous populations , 1990, Journal of mathematical biology.

[35]  Greenwood,et al.  The Statistics of Anti-Typhoid and Anti-Cholera Inoculations, and the Interpretation of Such Statistics in General , 1915, Proceedings of the Royal Society of Medicine.

[36]  S. Mboup,et al.  A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. , 1997, Vaccine.

[37]  J. Vaupel,et al.  The impact of heterogeneity in individual frailty on the dynamics of mortality , 1979, Demography.

[38]  D. Moher,et al.  The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration , 2001, Annals of Internal Medicine.

[39]  G. Eldering,et al.  A STUDY IN ACTIVE IMMUNIZATION AGAINST PERTUSSIS , 1939 .

[40]  W. Gilks,et al.  Random-effects models, for longitudinal data using Gibbs sampling. , 1993, Biometrics.

[41]  J. Hughes,et al.  Using baseline data to design a group randomized trial , 2005, Statistics in medicine.

[42]  M E Halloran,et al.  Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control. , 2000, Vaccine.

[43]  Mohammad Yunus,et al.  Controlling Endemic Cholera with Oral Vaccines , 2007, PLoS medicine.

[44]  P. Fine,et al.  Reflections on the efficacy of pertussis vaccines. , 1987, Reviews of infectious diseases.

[45]  M E J Newman,et al.  Predicting epidemics on directed contact networks. , 2006, Journal of theoretical biology.

[46]  P B Gilbert,et al.  Comparison of competing risks failure time methods and time-independent methods for assessing strain variations in vaccine protection. , 2000, Statistics in medicine.

[47]  M. Artenstein,et al.  Human immunity to the meningococcus. II. Development of natural immunity. , 1969 .

[48]  Daniel O Scharfstein,et al.  Incorporating prior beliefs about selection bias into the analysis of randomized trials with missing outcomes. , 2003, Biostatistics.

[49]  Michael G Hudgens,et al.  Causal Vaccine Effects on Binary Postinfection Outcomes , 2006, Journal of the American Statistical Association.

[50]  M. Elizabeth Halloran,et al.  A Frailty Mixture Model for Estimating Vaccine Efficacy , 1996 .

[51]  S Greenland,et al.  On the need for the rare disease assumption in case-control studies. , 1982, American journal of epidemiology.

[52]  Donald B. Rubin,et al.  Comment : Neyman ( 1923 ) and Causal Inference in Experiments and Observational Studies , 2007 .

[53]  D. Kyle,et al.  Field trials of an asexual blood stage malaria vaccine: studies of the synthetic peptide polymer SPf66 in Thailand and the analytic plan for a phase IIb efficacy study , 1995, Parasitology.

[54]  Odd O. Aalen,et al.  Modelling Heterogeneity in Survival Analysis by the Compound Poisson Distribution , 1992 .

[55]  J. Todd,et al.  Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial , 1995, The Lancet.

[56]  L. Magder,et al.  Effectiveness of school-based influenza vaccination. , 2006, The New England journal of medicine.

[57]  A. Rotnitzky,et al.  Semiparametric estimation of treatment effects given base‐line covariates on an outcome measured after a post‐randomization event occurs , 2007, Journal of the Royal Statistical Society. Series B, Statistical methodology.

[58]  M E Halloran,et al.  Using validation sets for outcomes and exposure to infection in vaccine field studies. , 2001, American journal of epidemiology.

[59]  M E Halloran,et al.  A Markov model for measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV vaccines. , 1999, Statistics in medicine.

[60]  R. Borges,et al.  A population-based clinical trial with the SPf66 synthetic Plasmodium falciparum malaria vaccine in Venezuela. , 1994, The Journal of infectious diseases.

[61]  P. MANSON-BAHR,et al.  Natural History of Infectious Disease , 1953, Nature.

[62]  R. May,et al.  Infectious Diseases of Humans: Dynamics and Control , 1991, Annals of Internal Medicine.

[63]  B. Murphy,et al.  Evaluation of the infectivity, immunogenicity, and efficacy of live cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in adult volunteers. , 1990, The Journal of infectious diseases.

[64]  Aravind Srinivasan,et al.  Modelling disease outbreaks in realistic urban social networks , 2004, Nature.

[65]  Safety, immunogenicity, and efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b vaccine in a United States population: possible implications for optimal use. , 1992, The Journal of infectious diseases.

[66]  P. Fine.  The interval between successive cases of an infectious disease. , 2003, American journal of epidemiology.

[67]  Alan Agresti,et al.  Categorical Data Analysis , 2003 .

[68]  Geert Molenberghs,et al.  Evaluation of Surrogate Endpoints , 2006, Handbook of Statistical Methods for Randomized Controlled Trials.

[69]  P. Romero,et al.  Induction of protective immunity against experimental infection with malaria using synthetic peptides , 1987, Nature.

[70]  Peter B Gilbert,et al.  ASSESSING SURROGATE ENDPOINTS IN VACCINE TRIALS WITH CASE-COHORT SAMPLING AND THE COX MODEL. , 2008, The annals of applied statistics.

[71]  M. Elizabeth Halloran,et al.  Comparison of Two Smoothing Methods for Exploring Waning Vaccine Effects , 1999 .

[72]  Fabrice Carrat,et al.  INFLUENZA BURDEN OF ILLNESS: ESTIMATES FROM A NATIONAL PROSPECTIVE SURVEY OF HOUSEHOLD CONTACTS IN FRANCE , 2002, Archives of internal medicine.

[73]  D Scharfstein,et al.  Methods for Conducting Sensitivity Analysis of Trials with Potentially Nonignorable Competing Causes of Censoring , 2001, Biometrics.

[74]  R. Hayes,et al.  Simple sample size calculation for cluster-randomized trials. , 1999, International journal of epidemiology.

[75]  S Greenland,et al.  Interpretation and choice of effect measures in epidemiologic analyses. , 1987, American journal of epidemiology.

[76]  P. Holland.  Statistics and Causal Inference , 1985 .

[77]  C. Woodbury.  Suburbanization and suburbia. , 1955, American journal of public health and the nation's health.

[78]  N. Andrews,et al.  Validation of Serological Correlate of Protection for Meningococcal C Conjugate Vaccine by Using Efficacy Estimates from Postlicensure Surveillance in England , 2003, Clinical Diagnostic Laboratory Immunology.

[79]  M E Halloran,et al.  The behaviour of common measures of association used to assess a vaccination programme under complex disease transmission patterns--a computer simulation study of malaria vaccines. , 1990, International journal of epidemiology.

[80]  W. P. Glezen,et al.  Trivalent Live Attenuated Intranasal Influenza Vaccine Administered During the 2003–2004 Influenza Type A (H3N2) Outbreak Provided Immediate, Direct, and Indirect Protection in Children , 2007, Pediatrics.

[81]  A R Hinman,et al.  Assessing vaccine efficacy in the field. Further observations. , 1988, Epidemiologic reviews.

[82]  M. Halloran,et al.  Design and interpretation of vaccine field studies. , 1999, Epidemiologic reviews.

[83]  J. Best,et al.  STRATEGY FOR RUBELLA VACCINATION , 1983, The Lancet.

[84]  G T Golm,et al.  Semi-parametric models for mismeasured exposure information in vaccine trials. , 1998, Statistics in medicine.

[85]  K. Warren,et al.  A study of illness in a group of Cleveland families. XXII. Antibodies to Toxoplasma gondii in 40 families observed for ten years. , 1953, The New England journal of medicine.

[86]  E. S. Pearson,et al.  THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL , 1934 .

[87]  Pedro A Piedra,et al.  Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. , 2005, Vaccine.

[88]  M E Halloran,et al.  Optimal vaccine trial design when estimating vaccine efficacy for susceptibility and infectiousness from multiple populations. , 1998, Statistics in medicine.

[89]  Hokwon A. Cho,et al.  Sequential Confidence Limits for the Ratio of Two Binomial Proportions , 2008 .

[90]  B. Cissé,et al.  Role of schools in the transmission of measles in rural Senegal: implications for measles control in developing countries. , 1999, American journal of epidemiology.

[91]  I M Longini,et al.  Models for the statistical analysis of infectious disease data. , 1988, Biometrics.

[92]  F. Simondon,et al.  Practical experiences in obtaining informed consent for a vaccine trial in rural Africa. , 1997, The New England journal of medicine.

[93]  J M Robins,et al.  Identifiability, exchangeability, and epidemiological confounding. , 1986, International journal of epidemiology.

[94]  R. Borrow,et al.  Serologic correlates of protection for evaluating the response to meningococcal vaccines , 2004, Expert review of vaccines.

[95]  Lihan K. Yan,et al.  Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. , 2000, The Journal of infectious diseases.

[96]  Claude Carbón,et al.  Reduction of antibiotic use in the community reduces the rate of colonization with penicillin G-nonsusceptible Streptococcus pneumoniae. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[97]  J. Heyse,et al.  Reduction in burden of illness: a new efficacy measure for prevention trials. , 1994, Statistics in medicine.

[98]  Peter B Gilbert,et al.  Evaluating a surrogate endpoint at three levels, with application to vaccine development , 2008, Statistics in medicine.

[99]  M. Gail,et al.  Biased estimates of treatment effect in randomized experiments with nonlinear regressions and omitted covariates , 1984 .

[100]  R. Chaisson,et al.  Statistical design of THRio: a phased implementation clinic-randomized study of a tuberculosis preventive therapy intervention , 2007, Clinical trials.

[101]  Nicholas P. Jewell,et al.  On the Bias of Commonly Used Measures of Association for 2 x 2 Tables , 1986 .

[102]  I. Longini,et al.  A generalized stochastic model for the analysis of infectious disease final size data. , 1991, Biometrics.

[103]  B. Schwartz,et al.  Intussusception among infants given an oral rotavirus vaccine. , 2001, The New England journal of medicine.

[104]  Siber Gr.  Methods for estimating serological correlates of protection. , 1997 .

[105]  I M Longini,et al.  A discrete-time model for the statistical analysis of infectious disease incidence data. , 1992, Biometrics.

[106]  J. Heyse,et al.  Use of statistical models for evaluating antibody response as a correlate of protection against varicella , 2002, Statistics in medicine.

[107]  Juan J. Angulo,et al.  On estimating the contagiousness of a disease transmitted from person to person , 1981 .

[108]  T. Fleming,et al.  Intermediate-size trials for the evaluation of HIV vaccine candidates: a workshop summary. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[109]  A. Melegaro,et al.  Estimating the transmission parameters of pneumococcal carriage in households , 2004, Epidemiology and Infection.

[110]  Christl A. Donnelly,et al.  Real-time Estimates in Early Detection of SARS , 2006, Emerging infectious diseases.

[111]  I NICOLETTI,et al.  The Planning of Experiments , 1936, Rivista di clinica pediatrica.

[112]  M. Petrova,et al.  [Whooping cough in adults]. , 1977, Sovetskaia meditsina.

[113]  P G Smith,et al.  Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies. , 1984, International journal of epidemiology.

[114]  Allan Donner,et al.  Some aspects of the design and analysis of cluster randomization trials , 2002 .

[115]  C. Macken,et al.  Mitigation strategies for pandemic influenza in the United States. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[116]  James M. Robins,et al.  Semiparametric Regression for Repeated Outcomes With Nonignorable Nonresponse , 1998 .

[117]  N. Gay,et al.  Epidemiological determinants of pertussis. , 1997, Developments in biological standardization.

[118]  H. P. Hudson,et al.  An application of the theory of probabilities to the study of a priori pathometry.—Part I , 1917 .

[119]  N. Bailey.  The mathematical theory of epidemics , 1957 .

[120]  A. Melegaro,et al.  A longitudinal household study of Streptococcus pneumoniae nasopharyngeal carriage in a UK setting , 2005, Epidemiology and Infection.

[121]  N G Becker,et al.  Immunization levels for preventing epidemics in a community of households made up of individuals of various types. , 1996, Mathematical biosciences.

[122]  J. Robins,et al.  Marginal Structural Models and Causal Inference in Epidemiology , 2000, Epidemiology.

[123]  W. Gruber,et al.  Correlation of Cellular Immune Responses with Protection against Culture-Confirmed Influenza Virus in Young Children , 2008, Clinical and Vaccine Immunology.

[124]  M. Hudgens,et al.  Assessing Vaccine Effects in Repeated Low‐Dose Challenge Experiments , 2009, Biometrics.

[125]  T. Vesikari,et al.  Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. , 1990, Scandinavian journal of infectious diseases.

[126]  M U Khan,et al.  Field trial of oral cholera vaccines in Bangladesh: results of one year of follow-up. , 1988, The Journal of infectious diseases.

[127]  R. Schneerson,et al.  Immunization of children with pertussis toxoid decreases spread of pertussis within the family. , 1998, The Pediatric infectious disease journal.

[128]  Joshua M. Epstein,et al.  Containing a large bioterrorist smallpox attack: a computer simulation approach. , 2007, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[129]  M. R. Novick,et al.  The Role of Exchangeability in Inference , 1981 .

[130]  L. Skovgaard.  NONLINEAR MODELS FOR REPEATED MEASUREMENT DATA. , 1996 .

[131]  L. Moulton,et al.  Evaluation of the Indirect Effects of a Pneumococcal Vaccine in a Community-Randomized Study , 2006, Journal of biopharmaceutical statistics.

[132]  David A. Schoenfeld,et al.  Partial residuals for the proportional hazards regression model , 1982 .

[133]  H. Hallander,et al.  Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. , 1998, Vaccine.

[134]  B. Murphy,et al.  ADVANTAGE OF LIVE ATTENUATED COLD-ADAPTED INFLUENZA A VIRUS OVER INACTIVATED VACCINE FOR A/WASHINGTON/80 (H3N2) WILD-TYPE VIRUS INFECTION , 1984, The Lancet.

[135]  K. O'Connor,et al.  HERD IMMUNITY , 2020 .

[136]  D. Basu.  Randomization Analysis of Experimental Data: The Fisher Randomization Test , 1980 .

[137]  K. Brownlee.  Statistics of the 1954 Polio Vaccine Trials , 1955 .

[138]  D. Cummings,et al.  Strategies for mitigating an influenza pandemic , 2006, Nature.

[139]  A. Agresti,et al.  Approximate is Better than “Exact” for Interval Estimation of Binomial Proportions , 1998 .

[140]  Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. , 1999, JAMA.

[141]  M. Fay,et al.  Accounting for Variability in Sample Size Estimation with Applications to Nonadherence and Estimation of Variance and Effect Size , 2007, Biometrics.

[142]  E. Miller,et al.  Efficacy of pertussis vaccination in England. Report from the PHLS Epidemiological Research Laboratory and 21 area health authorities. , 1982, British medical journal.

[143]  D. Schenzle.  An age-structured model of pre- and post-vaccination measles transmission. , 1984, IMA journal of mathematics applied in medicine and biology.

[144]  I. Longini,et al.  Tecumseh study of illness. XIII. Influenza infection and disease, 1976-1981. , 1985, American journal of epidemiology.

[145]  David M. Murray,et al.  Design and Analysis of Group- Randomized Trials , 1998 .

[146]  Bradley P. Carlin,et al.  BAYES AND EMPIRICAL BAYES METHODS FOR DATA ANALYSIS , 1996, Stat. Comput..

[147]  J. Robins,et al.  Sensitivity Analysis for Selection bias and unmeasured Confounding in missing Data and Causal inference models , 2000 .

[148]  F. Hayden,et al.  The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. , 1998, The New England journal of medicine.

[149]  N G Becker,et al.  The effect of random vaccine response on the vaccination coverage required to prevent epidemics. , 1998, Mathematical biosciences.

[150]  J. Koella,et al.  Models of the within-host dynamics of persistent mycobacterial infections , 1996, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[151]  David M. Oshinsky.  Polio: An American Story , 2005 .

[152]  David Goldblatt,et al.  Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. , 2003, Vaccine.

[153]  J. Robins,et al.  Adjusting for Nonignorable Drop-Out Using Semiparametric Nonresponse Models , 1999 .

[154]  Ả. Svensson.  A note on generation times in epidemic models. , 2007, Mathematical Biosciences.

[155]  L H Moulton,et al.  Design of a group-randomized Streptococcus pneumoniae vaccine trial. , 2001, Controlled clinical trials.

[156]  Bryan E Shepherd,et al.  Sensitivity Analyses Comparing Time-to-Event Outcomes Existing Only in a Subset Selected Postrandomization , 2007, Journal of the American Statistical Association.

[157]  W. Mcneill.  Plagues and Peoples , 1977, The Review of Politics.

[158]  M E Halloran,et al.  Measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV-1 vaccines. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[159]  C. Farrington.  Estimation of vaccine effectiveness using the screening method. , 1993, International journal of epidemiology.

[160]  P. Damlen,et al.  Gibbs sampling for Bayesian non‐conjugate and hierarchical models by using auxiliary variables , 1999 .

[161]  A. Nicoll,et al.  A community trial of the impact of improved sexually transmitted disease treatment on the HIV epidemic in rural Tanzania: 1. Design , 1995, AIDS.

[162]  E. Lewis,et al.  Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children , 2000, The Pediatric infectious disease journal.

[163]  A. Monto,et al.  Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. , 2002, The Journal of infectious diseases.

[164]  Pedro A Piedra,et al.  Live Attenuated Influenza Vaccine, Trivalent, Is Safe in Healthy Children 18 Months to 4 Years, 5 to 9 Years, and 10 to 18 Years of Age in a Community-Based, Nonrandomized, Open-Label Trial , 2005, Pediatrics.

[165]  A. Nizam,et al.  Containing Pandemic Influenza at the Source , 2005, Science.

[166]  M Elizabeth Halloran,et al.  A Resampling-Based Test to Detect Person-To-Person Transmission of Infectious Disease. , 2007, The annals of applied statistics.

[167]  Ian W McKeague,et al.  PROPORTIONAL HAZARDS MODELS WITH CONTINUOUS MARKS. , 2009, Annals of statistics.

[168]  J. Wittes,et al.  Correlates, surrogates, and vaccines. , 2007, The Journal of infectious diseases.

[169]  R. L. Prentice,et al.  Retrospective studies and failure time models , 1978 .

[170]  B. Efron.  Forcing a sequential experiment to be balanced , 1971 .

[171]  R. J. Hayes,et al.  Design and analysis issues in cluster-randomized trials of interventions against infectious diseases , 2000, Statistical methods in medical research.

[172]  Sander Greenland,et al.  Confounding in epidemiologic studies. Response , 1989 .

[173]  M. Ewell.  Comparing methods for calculating confidence intervals for vaccine efficacy. , 1996, Statistics in medicine.

[174]  Russell D. Wolfinger,et al.  Fitting Nonlinear Mixed Models with the New NLMIXED Procedure , 1999 .

[175]  E. Lewis,et al.  Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. , 2000, The Pediatric infectious disease journal.

[176]  Yang Yang,et al.  A data-augmentation method for infectious disease incidence data from close contact groups , 2007, Comput. Stat. Data Anal..

[177]  M Elizabeth Halloran,et al.  Design and evaluation of prophylactic interventions using infectious disease incidence data from close contact groups , 2006, Journal of the Royal Statistical Society. Series C, Applied statistics.

[178]  P. Brémaud.  Point Processes and Queues , 1981 .

[179]  O. Aalen,et al.  Heterogeneity in survival analysis. , 1988, Statistics in medicine.

[180]  D. Kyle,et al.  Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand , 1996, The Lancet.

[181]  Haitao Chu,et al.  On estimation of vaccine efficacy using validation samples with selection bias. , 2006, Biostatistics.

[182]  D. Sack,et al.  Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis , 2005, The Lancet.

[183]  G. Siber.  Methods for estimating serological correlates of protection. , 1997, Developments in biological standardization.

[184]  M E Halloran,et al.  Epidemiologic effects of vaccines with complex direct effects in an age-structured population. , 1994, Mathematical biosciences.

[185]  J S Koopman,et al.  Assessing HIV vaccine effects. , 1995, American journal of epidemiology.

[186]  M. Halloran,et al.  Estimation of vaccine efficacy in the presence of waning: application to cholera vaccines. , 1998, American journal of epidemiology.

[187]  Donald B. Rubin,et al.  Bayesian Inference for Causal Effects: The Role of Randomization , 1978 .

[188]  R. Peto,et al.  Experimental Survival Curves for Interval‐Censored Data , 1973 .

[189]  V. Romanus,et al.  Pertussis in Sweden after the cessation of general immunization in 1979. , 1987, The Pediatric infectious disease journal.

[190]  R. Simpson,et al.  Infectiousness of communicable diseases in the household (measles, chickenpox, and mumps). , 1952, Lancet.

[191]  K. Auranen,et al.  Longitudinal Study on Pneumococcal Carriage During the First Year of Life in Bangladesh , 2007, The Pediatric infectious disease journal.

[192]  A Method for Estimating Time Dependent Intervention Benefits under Arbitrarily Varying Age and Exogenous Components of Hazard , 2001, Lifetime data analysis.

[193]  G. Cook.  Methods for Field Trials of Interventions Against Tropical Diseases - A toolbox , 1993 .

[194]  J. Robbins,et al.  Mass vaccination of children with pertussis toxoid--decreased incidence in both vaccinated and nonvaccinated persons. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[195]  Alexander Grey,et al.  The Mathematical Theory of Infectious Diseases and Its Applications , 1977 .

[196]  J. T. Kemper,et al.  Error sources in the evaluation of secondary attack rates. , 1980, American journal of epidemiology.

[197]  M. Halloran,et al.  Malaria vaccines: lessons from field trials. , 1994, Cadernos de saude publica.

[198]  Subhash R. Lele,et al.  Maximum likelihood estimation in semiparametric selection bias models with application to AIDS vaccine trials , 1999 .

[199]  M. Hudgens,et al.  Sensitivity Analysis for the Assessment of Causal Vaccine Effects on Viral Load in HIV Vaccine Trials , 2003, Biometrics.

[200]  I. Longini,et al.  Household and community transmission parameters from final distributions of infections in households. , 1982, Biometrics.

[201]  J P Fox,et al.  Influenzavirus infections in Seattle families, 1975-1979. II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness. , 1982, American journal of epidemiology.

[202]  Semiparametric Methods for Multiple Exposure Mismeasurement and a Bivariate Outcome in HIV Vaccine Trials , 1999, Biometrics.

[203]  J. Hughes,et al.  Stepped Wedge Design , 2008 .

[204]  A. Razmpour,et al.  A Randomized, Double-Blind Study of the Safety, Transmissibility and Phenotypic and Genotypic Stability of Cold-Adapted Influenza Virus Vaccine , 2006, The Pediatric infectious disease journal.

[205]  Tom Britton,et al.  Estimating Vaccine Effects on Transmission of Infection from Household Outbreak Data , 2003, Biometrics.

[206]  J. Robins,et al.  Identifiability and Exchangeability for Direct and Indirect Effects , 1992, Epidemiology.

[207]  A. Nizam,et al.  Containing Bioterrorist Smallpox , 2002, Science.

[208]  S. Cauchemez,et al.  S. pneumoniae transmission according to inclusion in conjugate vaccines: Bayesian analysis of a longitudinal follow-up in schools , 2006, BMC infectious diseases.

[209]  Bin Li,et al.  HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges. , 2006, Virology.

[210]  F. Fenner.  Smallpox and its eradication , 1988 .

[211]  D. Kelly,et al.  Haemophilus influenzae type b conjugate vaccines , 2004, Immunology.

[212]  M E Halloran,et al.  Modeling malaria vaccines. II: Population effects of stage-specific malaria vaccines dependent on natural boosting. , 1989, Mathematical biosciences.

[213]  B. Murphy,et al.  Resistance of adults to challenge with influenza A wild-type virus after receiving live or inactivated virus vaccine , 1986, Journal of clinical microbiology.

[214]  A Donner,et al.  Cluster randomization trials in tropical medicine: a case study. , 1995, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[215]  M E Halloran,et al.  Study designs for dependent happenings. , 1991, Epidemiology.

[216]  S. Self,et al.  Sieve analysis: methods for assessing from vaccine trial data how vaccine efficacy varies with genotypic and phenotypic pathogen variation. , 2001, Journal of clinical epidemiology.

[217]  M E Halloran,et al.  Augmented HIV vaccine trial design for estimating reduction in infectiousness and protective efficacy. , 1998, Statistics in medicine.

[218]  W. S. Jordan,et al.  A study of illness in a group of Cleveland families. XVII. The occurrence of Asian influenza. , 1958, American journal of hygiene.

[219]  Nicole A. Lazar,et al.  Statistical Analysis With Missing Data , 2003, Technometrics.

[220]  M Greenwood,et al.  On the Statistical Measure of Infectiousness , 1931, Journal of Hygiene.

[221]  C. von Bonsdorff,et al.  Rubella immunity and morbidity: effects of vaccination in Finland. , 1988, Scandinavian journal of infectious diseases.

[222]  R. Walker,et al.  Live attenuated versus inactivated influenza vaccine in infants and young children. , 2007, The New England journal of medicine.

[223]  J. Wallinga,et al.  Different Epidemic Curves for Severe Acute Respiratory Syndrome Reveal Similar Impacts of Control Measures , 2004, American journal of epidemiology.

[224]  P E Fine,et al.  The efficacy of pertussis vaccines under conditions of household exposure. Further analysis of the 1978-80 PHLS/ERL study in 21 area health authorities in England. , 1988, International journal of epidemiology.

[225]  L. Elveback,et al.  EPIDEMIOLOGY; MAN AND DISEASE , 1971 .

[226]  F. Rogers.  Epidemiology: Man and Disease , 1970 .

[227]  F. Perkins.  Vaccination against whooping-cough. , 1969, British medical journal.

[228]  M. Ashraf Chaudhary,et al.  A SAS macro for constrained randomization of group-randomized designs , 2006, Comput. Methods Programs Biomed..

[229]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[230]  M E Halloran,et al.  Estimability and interpretation of vaccine efficacy using frailty mixing models. , 1996, American journal of epidemiology.

[231]  K. P. Murphy,et al.  Janeway's immunobiology , 2007 .

[232]  H. Hallander,et al.  Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine , 1997, The Lancet.

[233]  I M Longini,et al.  Statistical inference for infectious diseases. Risk-specific household and community transmission parameters. , 1988, American journal of epidemiology.

[234]  R. Ahmed,et al.  Models of immune memory: on the role of cross-reactive stimulation, competition, and homeostasis in maintaining immune memory. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[235]  C. Viboud,et al.  A Bayesian MCMC approach to study transmission of influenza: application to household longitudinal data , 2004, Statistics in medicine.

[236]  J. Oxford,et al.  Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. , 2001, JAMA.

[237]  D. Balding,et al.  Analyses of infectious disease data from household outbreaks by Markov chain Monte Carlo methods , 2000 .

[238]  N E Breslow,et al.  General relative risk functions for case-control studies. , 1985, American journal of epidemiology.

[239]  J. Mittler,et al.  Modeling T-cell proliferation: an investigation of the consequences of the Hayflick limit. , 1997, Journal of theoretical biology.

[240]  Peter B Gilbert,et al.  A framework for assessing immunological correlates of protection in vaccine trials. , 2007, The Journal of infectious diseases.

[241]  J. Robins,et al.  Semiparametric regression estimation in the presence of dependent censoring , 1995 .

[242]  D. Jemiolo,et al.  Prediction of pertussis vaccine efficacy using a correlates of protection model. , 2008, Vaccine.

[243]  J. Yorke,et al.  Gonorrhea Transmission Dynamics and Control , 1984 .

[244]  O. Leroy,et al.  Efficacy of measles vaccines after controlling for exposure. , 1993, American journal of epidemiology.

[245]  W. J. Langford.  Statistical Methods , 1959, Nature.

[246]  D. Musher.  Pneumococcal vaccine--direct and indirect ("herd") effects. , 2006, The New England journal of medicine.

[247]  A. Langworthy,et al.  An influenza simulation model for immunization studies. , 1976, American journal of epidemiology.

[248]  A. Monto,et al.  Effect of vaccination of a school-age population upon the course of an A2-Hong Kong influenza epidemic. , 1969, Bulletin of the World Health Organization.

[249]  M Elizabeth Halloran,et al.  Invited Commentary Invited Commentary: Challenges of using Contact Data to Understand Acute Respiratory Disease Transmission , 2006 .

[250]  T. Francis,et al.  An evaluation of the 1954 poliomyelitis vaccine trials. , 1955, American journal of public health and the nation's health.

[251]  R Brookmeyer,et al.  Analysis of infectious disease data from partner studies with unknown source of infection. , 1993, Biometrics.

[252]  P Cantrelle,et al.  Three decades of research on population and health: the ORSTOM experience in rural Senegal: 1962-1991. , 1991 .

[253]  Ross L. Prentice,et al.  Aggregate data studies of disease risk factors , 1995 .

[254]  Lawrence H Moulton,et al.  Covariate-based constrained randomization of group-randomized trials , 2004, Clinical trials.

[255]  M. Gail.  The Effect of Pooling Across Strata in Perfectly Balanced Studies , 1988 .

[256]  T D Koepsell,et al.  The effect of matching on the power of randomized community intervention studies. , 1993, Statistics in medicine.

[257]  A R Hinman,et al.  Field evaluation of vaccine efficacy. , 1985, Bulletin of the World Health Organization.

[258]  M. Halloran,et al.  Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials. , 2006, American journal of epidemiology.

[259]  V. Farewell,et al.  The use of mixture models for the analysis of survival data with long-term survivors. , 1982, Biometrics.

[260]  D. Jenkinson.  Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study , 1988, British medical journal.

[261]  Dean Follmann,et al.  Augmented Designs to Assess Immune Response in Vaccine Trials , 2006, Biometrics.

[262]  M. Hudgens,et al.  Toward Causal Inference With Interference , 2008, Journal of the American Statistical Association.

[263]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[264]  D. Sack,et al.  The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. , 1991, The New England journal of medicine.

[265]  J J Angulo,et al.  Variola minor in Bragança Paulista County, 1956: overall description of the epidemic and of its study. , 1976, International journal of epidemiology.

[266]  A. Nizam,et al.  Containing pandemic influenza with antiviral agents. , 2004, American journal of epidemiology.

[267]  J. Hughes,et al.  Design and analysis of stepped wedge cluster randomized trials. , 2007, Contemporary clinical trials.

[268]  A. Schuchat,et al.  Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska Natives: progress towards elimination of a health disparity. , 2005, Vaccine.

[269]  M. Artenstein,et al.  HUMAN IMMUNITY TO THE MENINGOCOCCUS I. THE ROLE OF HUMORAL ANTIBODIES , 1969 .

[270]  M. Connock,et al.  Universal vaccination of children against influenza: are there indirect benefits to the community? A systematic review of the evidence. , 2006, Vaccine.

[271]  D. Rubin,et al.  Principal Stratification in Causal Inference , 2002, Biometrics.

[272]  P. Rhodes,et al.  A 'post-honeymoon period' measles outbreak in Muyinga sector, Burundi. , 1994, International journal of epidemiology.

[273]  Elja Arjas,et al.  Transmission of Pneumococcal Carriage in Families: A Latent Markov Process Model for Binary Longitudinal Data , 2000 .

[274]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[275]  C. Macken,et al.  Modeling targeted layered containment of an influenza pandemic in the United States , 2008, Proceedings of the National Academy of Sciences.

[276]  R. Heyderman,et al.  Capture-recapture analysis and pneumococcal meningitis estimates in England. , 2004, Emerging infectious diseases.

[277]  H. Chu,et al.  Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures. , 2003, American journal of epidemiology.

[278]  M. Kenward,et al.  An Introduction to the Bootstrap , 2007 .

[279]  S. Hadler,et al.  The prevention of hepatitis B with vaccine. Report of the centers for disease control multi-center efficacy trial among homosexual men. , 1982, Annals of internal medicine.

[280]  Hiroshi Sugiyama,et al.  Some Statistical Contributions to the Health Sciences , 1960 .

[281]  W. Blackwelder,et al.  A placebo-controlled trial of a pertussis-toxoid vaccine. , 1995, The New England journal of medicine.

[282]  J P Fox,et al.  Influenzavirus infections in Seattle families, 1975-1979. I. Study design, methods and the occurrence of infections by time and age. , 1982, American journal of epidemiology.

[283]  Andrea Rotnitzky,et al.  Sensitivity Analyses Comparing Outcomes Only Existing in a Subset Selected Post‐Randomization, Conditional on Covariates, with Application to HIV Vaccine Trials , 2006, Biometrics.

[284]  C. Farrington,et al.  The measurement and interpretation of age-specific vaccine efficacy. , 1992, International journal of epidemiology.

[285]  S. Greenland,et al.  On measures and models for the effectiveness of vaccines and vaccination programmes. , 1988, International journal of epidemiology.

[286]  W. Blackwelder,et al.  Pertussis antibodies, protection, and vaccine efficacy after household exposure. , 1992, American journal of diseases of children.

[287]  T. Hien,et al.  Prevalence of enteric hepatitis A and E viruses in the Mekong River delta region of Vietnam. , 1999, The American journal of tropical medicine and hygiene.

[288]  David J. Spiegelhalter,et al.  WinBUGS user manual version 1.4 , 2003 .

[289]  M. Lipsitch.  Interpreting results from trials of pneumococcal conjugate vaccines: a statistical test for detecting vaccine-induced increases in carriage of nonvaccine serotypes. , 2000, American journal of epidemiology.

[290]  C. Farrington,et al.  Estimation of Waning Vaccine Efficacy , 2002 .

[291]  S. Chick,et al.  Bias reduction for risk ratio and vaccine effect estimators , 2001, Statistics in medicine.

[292]  Geert Molenberghs,et al.  Sensitivity analysis for incomplete contingency tables: the Slovenian plebiscite case , 2001 .

[293]  E. Arjas,et al.  A statistical model of transmission of Hib bacteria in a family. , 1996, Statistics in medicine.

[294]  D B Rubin,et al.  Practical implications of modes of statistical inference for causal effects and the critical role of the assignment mechanism. , 1991, Biometrics.

[295]  Thomas R. Fleming,et al.  Auxiliary outcome data and the mean score method , 1994 .

[296]  A. Monto,et al.  Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. , 1993, The Journal of infectious diseases.

[297]  M. Bangs,et al.  Early detection of dengue infections using cluster sampling around index cases. , 2005, The American journal of tropical medicine and hygiene.

[298]  Elja Arjas,et al.  Survival models and martingale dynamics , 1989 .

[299]  J. Robbins,et al.  Efficacy of a monocomponent pertussis toxoid vaccine after household exposure to pertussis. , 1997, The Journal of pediatrics.

[300]  S. M. Martin,et al.  Recommendations for the use of Taylor series confidence intervals for estimates of vaccine efficacy. , 1988, Bulletin of the World Health Organization.

[301]  F. Ball.  A unified approach to the distribution of total size and total area under the trajectory of infectives in epidemic models , 1986, Advances in Applied Probability.

[302]  Allan Donner,et al.  Cluster randomization trials in epidemiology: theory and application , 1994 .

[303]  M E Halloran,et al.  Interpretation and estimation of vaccine efficacy under heterogeneity. , 1992, American journal of epidemiology.

[304]  Michael G Hudgens,et al.  On the analysis of viral load endpoints in HIV vaccine trials , 2003, Statistics in medicine.

[305]  R. Prentice.  Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.

[306]  J. Clemens,et al.  Evaluating new vaccines for developing countries. Efficacy or effectiveness? , 1996, JAMA.

[307]  P. Rosenbaum.  The Consequences of Adjustment for a Concomitant Variable that Has Been Affected by the Treatment , 1984 .

[308]  L. Simonsen,et al.  The Japanese experience with vaccinating schoolchildren against influenza. , 2001, The New England journal of medicine.

[309]  J. Koopman,et al.  Dengue epidemics on the Pacific Coast of Mexico. , 1988, International journal of epidemiology.

[310]  R. May,et al.  Population Biology of Infectious Diseases , 1982, Dahlem Workshop Reports.

[311]  P. Aaby,et al.  No long-term excess mortality after measles infection: a community study from Senegal. , 1996, American journal of epidemiology.

[312]  Mark E. J. Newman,et al.  Structure and Dynamics of Networks , 2009 .

[313]  A. Kristal,et al.  Selected methodological issues in evaluating community-based health promotion and disease prevention programs. , 1992, Annual review of public health.

[314]  Michael Proschan,et al.  Chop‐Lump Tests for Vaccine Trials , 2009, Biometrics.

[315]  S. Zeger,et al.  Longitudinal data analysis using generalized linear models , 1986 .

[316]  J. Robins.  A new approach to causal inference in mortality studies with a sustained exposure period—application to control of the healthy worker survivor effect , 1986 .

[317]  Haitao Chu,et al.  Estimating Vaccine Efficacy From Secondary Attack Rates , 2003 .

[318]  N. Andrews,et al.  Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis , 2003, BMJ : British Medical Journal.

[319]  M E Halloran,et al.  Modeling malaria vaccines. I: New uses for old ideas. , 1989, Mathematical biosciences.

[320]  P. Diggle.  Analysis of Longitudinal Data , 1995 .

[322]  M. Kretzschmar,et al.  Concurrent partnerships and the spread of HIV , 1997, AIDS.